Loading...
•
Sep 30, 2022
Gilead Sciences Q3 2022 Earnings Report
Gilead Sciences' performance was driven by growth in HIV and oncology products, offsetting lower Veklury sales
Key Takeaways
Gilead Sciences announced its third quarter 2022 financial results, with product sales excluding Veklury increasing 11% year-over-year to $6.1 billion. Biktarvy sales increased 22% year-over-year to $2.8 billion, and oncology sales increased 79% year-over-year to $578 million. Total revenue decreased 5% to $7.0 billion compared to the same period in 2021, primarily due to lower Veklury sales.
Total third quarter 2022 revenue decreased 5% to $7.0 billion compared to the same period in 2021.
Diluted Earnings Per Share decreased to $1.42 for the third quarter of 2022 compared to $2.05 for the same period in 2021.
Non-GAAP diluted EPS decreased to $1.90 for the third quarter of 2022 compared to $2.65 for the same period in 2021.
As of September 30, 2022, Gilead had $6.9 billion of cash, cash equivalents and marketable debt securities.
Gilead Sciences
Gilead Sciences
Gilead Sciences Revenue by Segment
Gilead Sciences Revenue by Geographic Location
Revenue by Segment
HIV Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
For the full-year, Gilead has updated its guidance and now expects: Total product sales between $25.9 billion and $26.2 billion and Non-GAAP earnings per share between $6.95 and $7.15.
Positive Outlook
- Total product sales between $25.9 billion and $26.2 billion, compared to $24.5 billion and $25.0 billion previously.
- Total product sales, excluding Veklury, between $22.5 billion to $22.8 billion, compared to $22.0 billion and $22.5 billion previously.
- Total Veklury sales of approximately $3.4 billion, compared to approximately $2.5 billion previously.
- Non-GAAP earnings per share between $6.95 and $7.15, compared to $6.35 and $6.75 previously.
- Earnings per share between $3.35 and $3.55, compared to $2.90 and $3.30 previously.